192.97 USD
-3.11 (-1.59%)
192.97 USD
0 (0%)
Taking everything into account, LGND scores 6 out of 10 in our fundamental rating. LGND was compared to 190 industry peers in the Pharmaceuticals industry. While LGND belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. LGND is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, LGND could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
- In the past year LGND was profitable.
- In the past year LGND had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: LGND reported negative net income in multiple years.
- In the past 5 years LGND always reported a positive cash flow from operatings.
1.2 Ratios
- LGND has a Return On Assets of 3.29%. This is amongst the best in the industry. LGND outperforms 83.16% of its industry peers.
- LGND has a better Return On Equity (5.11%) than 83.16% of its industry peers.
- LGND has a better Return On Invested Capital (1.58%) than 78.42% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for LGND is significantly below the industry average of 12.84%.
- The 3 year average ROIC (1.12%) for LGND is below the current ROIC(1.58%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROIC | 1.58% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
1.3 Margins
- With an excellent Profit Margin value of 19.34%, LGND belongs to the best of the industry, outperforming 90.53% of the companies in the same industry.
- With an excellent Operating Margin value of 11.48%, LGND belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
- LGND's Operating Margin has declined in the last couple of years.
- The Gross Margin of LGND (94.27%) is better than 96.32% of its industry peers.
- LGND's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% |
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), LGND is destroying value.
- Compared to 1 year ago, LGND has more shares outstanding
- Compared to 5 years ago, LGND has more shares outstanding
- LGND has a worse debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 5.77 indicates that LGND is not in any danger for bankruptcy at the moment.
- LGND has a better Altman-Z score (5.77) than 75.79% of its industry peers.
- LGND has a debt to FCF ratio of 14.48. This is a negative value and a sign of low solvency as LGND would need 14.48 years to pay back of all of its debts.
- With a decent Debt to FCF ratio value of 14.48, LGND is doing good in the industry, outperforming 77.37% of the companies in the same industry.
- LGND has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
- LGND has a Debt to Equity ratio of 0.47. This is in the lower half of the industry: LGND underperforms 62.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Altman-Z | 5.77 |
ROIC/WACC0.17
WACC9.38%
2.3 Liquidity
- A Current Ratio of 24.69 indicates that LGND has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 24.69, LGND belongs to the top of the industry, outperforming 93.68% of the companies in the same industry.
- LGND has a Quick Ratio of 24.30. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Quick ratio value of 24.30, LGND belongs to the best of the industry, outperforming 92.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 |
3. Growth
3.1 Past
- LGND shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.26%, which is quite impressive.
- The Earnings Per Share has been growing by 13.44% on average over the past years. This is quite good.
- LGND shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.83%.
- LGND shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.80% yearly.
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
3.2 Future
- LGND is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.28% yearly.
- LGND is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.13% yearly.
EPS Next Y30.63%
EPS Next 2Y21.4%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue Next Year53.36%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 26.47 indicates a quite expensive valuation of LGND.
- Compared to the rest of the industry, the Price/Earnings ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 77.89% of the companies listed in the same industry.
- LGND is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.47, which is the current average of the S&P500 Index.
- LGND is valuated rather expensively with a Price/Forward Earnings ratio of 22.93.
- Based on the Price/Forward Earnings ratio, LGND is valued a bit cheaper than 75.26% of the companies in the same industry.
- LGND's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.26.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.47 | ||
| Fwd PE | 22.93 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, LGND is valued a bit cheaper than the industry average as 76.84% of the companies are valued more expensively.
- LGND's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. LGND is cheaper than 74.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 123.46 | ||
| EV/EBITDA | 49.41 |
4.3 Compensation for Growth
- LGND's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of LGND may justify a higher PE ratio.
- A more expensive valuation may be justified as LGND's earnings are expected to grow with 19.77% in the coming years.
PEG (NY)0.86
PEG (5Y)1.97
EPS Next 2Y21.4%
EPS Next 3Y19.77%
5. Dividend
5.1 Amount
- LGND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
192.97
-3.11 (-1.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners106.73%
Inst Owner Change1.31%
Ins Owners1.62%
Ins Owner Change-1.28%
Market Cap3.80B
Revenue(TTM)251.23M
Net Income(TTM)48.58M
Analysts85.71
Price Target248.31 (28.68%)
Short Float %5.7%
Short Ratio5.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.83%
Min EPS beat(2)10.36%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)19.98%
Min EPS beat(4)4.63%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)37.45%
EPS beat(12)12
Avg EPS beat(12)53.58%
EPS beat(16)15
Avg EPS beat(16)61.91%
Revenue beat(2)2
Avg Revenue beat(2)25.66%
Min Revenue beat(2)6.44%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)18.43%
Min Revenue beat(4)6.44%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.31%
Revenue beat(12)11
Avg Revenue beat(12)12.65%
Revenue beat(16)14
Avg Revenue beat(16)16.25%
PT rev (1m)2.5%
PT rev (3m)32.94%
EPS NQ rev (1m)5.26%
EPS NQ rev (3m)-23.81%
EPS NY rev (1m)-3.25%
EPS NY rev (3m)6.52%
Revenue NQ rev (1m)-0.24%
Revenue NQ rev (3m)-11.05%
Revenue NY rev (1m)-2.41%
Revenue NY rev (3m)16.66%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.47 | ||
| Fwd PE | 22.93 | ||
| P/S | 15.12 | ||
| P/FCF | 123.46 | ||
| P/OCF | 118.99 | ||
| P/B | 4 | ||
| P/tB | 9.29 | ||
| EV/EBITDA | 49.41 |
EPS(TTM)7.29
EY3.78%
EPS(NY)8.41
Fwd EY4.36%
FCF(TTM)1.56
FCFY0.81%
OCF(TTM)1.62
OCFY0.84%
SpS12.77
BVpS48.28
TBVpS20.77
PEG (NY)0.86
PEG (5Y)1.97
Graham Number88.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROCE | 1.99% | ||
| ROIC | 1.58% | ||
| ROICexc | 2.92% | ||
| ROICexgc | 9.48% | ||
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% | ||
| FCFM | 12.24% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
ROICexc(3y)1.91%
ROICexc(5y)2.67%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.87%
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Debt/EBITDA | 7.07 | ||
| Cap/Depr | 3.38% | ||
| Cap/Sales | 0.46% | ||
| Interest Coverage | 96.15 | ||
| Cash Conversion | 50.63% | ||
| Profit Quality | 63.32% | ||
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 | ||
| Altman-Z | 5.77 |
F-Score5
WACC9.38%
ROIC/WACC0.17
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
EPS Next Y30.63%
EPS Next 2Y21.4%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
Revenue Next Year53.36%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%
EBIT growth 1Y64.02%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year674.52%
EBIT Next 3Y155.59%
EBIT Next 5Y79.19%
FCF growth 1Y-61.26%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-66.41%
OCF growth 3Y7.19%
OCF growth 5YN/A
LIGAND PHARMACEUTICALS / LGND FAQ
What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a fundamental rating of 6 / 10 to LGND.
What is the valuation status of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a valuation rating of 5 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.
How profitable is LIGAND PHARMACEUTICALS (LGND) stock?
LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 7 / 10.
What is the financial health of LIGAND PHARMACEUTICALS (LGND) stock?
The financial health rating of LIGAND PHARMACEUTICALS (LGND) is 6 / 10.